Medical Drugs News
-
Showcase
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring one for multiple sclerosis and developing a potential cure for diabetes, has received a patent from the Japan Patent Office for AstroRx® for the treatment of ALS and drug screening. The patent also protects AstroRx® for the treatment of multiple sclerosis. AstroRx® is ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
Drug developed by Galveston scientist to be tested for COVID-19 use
A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from the federal government to be released June 1. Chrysalin, or TP508, a regenerative thrombin peptide developed by scientist Darrell Carney, has been tested in human clinical trials for skin and bone tissue repair ...
-
High quality pharmaceutical packaging: PTP aluminum
Abstract: At present, blister packaging is becoming more and more common in the packaging of health food and pharmaceutical tablets and capsules. PTP aluminum foil is the sealing material on the pharmaceutical PVC sheet. Overview of PTP Aluminum Foil Among many traditional industries, the packaging industry is known as “the never-ending sunrise industry”, of which the pharmaceutical ...
-
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure, announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, awarded Chrysalis $912,157 to fund preclinical development of its investigational drug TP508 for SARS-CoV-2 ...
-
A Vital Training Opportunity for CGT Manufacturing - A Global Partnership with ISCT & CMaT
The International Society for Cell & Gene Therapy (ISCT) and The National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT) led by the Georgia Institute of Technology are pleased to launch the first joint-training program of our partnership, Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT. Developed by ...
-
Morgridge Postdoc Awarded First AAAS Science & Technology Policy Fellowship in the U.S. Department of the Treasury Das will be the first ever AAAS Fellow accepted into a position at the Department of the Treasury
Ask anyone participating in a cultural exchange: It’s helpful to know the local language. Morgridge Postdoctoral Fellow Amritava Das knows this well, and not just because he speaks five languages. His career has been defined by bridging the different languages of science and ethics, and he will soon be taking that expertise to the U.S. Department of the Treasury via a ...
-
New Startup Makes Developing Gene Therapies Faster and Easier
Today, cell and gene therapies treat and could even cure terminal diseases like leukemia and spinal muscular atrophy, but unlocking their full potential is still a challenge for therapy developers. Both types of therapies rely on living cells comprised of hundreds of thousands of biomolecules to work in unison. And in order for therapy developers to meet safety and production ...
-
Kadimastem Granted a Patent in Israel for the Treatment of ALS
NESS ZIONA, ISRAEL, March 9, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS). Specifically, the patent allows for the innovative ...
-
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
-
An Overview of Glioblastoma
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
-
The `good, bad and ugly` of prescription pain medications
The drugs doctors prescribe for treating the symptoms of pain, anxiety and psoriasis carry with them powerful and often destructive side-effects. Let’s review the current list and why at Medipure we’re convinced we need new medications and a new approach: The current first-line therapeutics for pain (Bupenophrene, hydrocodine and oxycodine) can produce adverse medical reactions ...
-
Pain management: at the core of canada`s opioid crisis
Dr. Andrea Furlan, Associate Professor of Medicine at the University of Toronto, commented recently that pain management is at the core of Canada’s opioid crisis and the key to a solution. In an article originally published in "The Conversation", an independent and non-profit Academic Journal and reprinted in the National Post, Dr. Furlan noted that two people die every day in ...
-
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific ...
-
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
-
Positive FDA Guidance For Covid-19 Clinical Program
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to ...
-
Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project
Profacgen, an experienced provider in biological research and drug discovery, provides various ubiquitin services to help customers accelerate research progress and obtain better results. Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of ...
By Profacgen
-
CD ComputaBio Introduces IPA Analysis Service to Speed Up Your Research
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company announced the launch of Ingenuity Pathway Analysis (IPA), which enables the analysis, integration, and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you